Paradigm’s focus is on developing injectable (subcutaneous) pentosan polysulfate sodium for the treatment of diseases where inflammation plays a major pathogenic role, indicating a need for the anti-inflammatory and tissue regenerative properties of PPS, such as in osteoarthritis (Phase III) and mucopolysaccharidosis (Phase II).